Corvus starts Phase 1b trial of soquelitinib in hidradenitis suppurativa patients
CRVS•Corvus Pharmaceuticals began enrolling a Phase 1b trial of soquelitinib in hidradenitis suppurativa, targeting up to 25 adults with moderate to severe disease. The 12-week study is expected to assess safety and early signs of clinical benefit; no results have been presented.
1. Trial begins enrollment
Corvus Pharmaceuticals began enrolling a Phase 1b trial of soquelitinib in adults with moderate to severe hidradenitis suppurativa. The study targets up to 25 participants, with a 12-week treatment period.
2. Expanding development
The program adds a fourth clinical indication for soquelitinib, alongside late-stage work in peripheral T cell lymphoma and mid-stage trials in atopic dermatitis. The company aims to support an oral treatment option using a novel immune-modulating approach.
